Introduction {#sec1-2048004019856496}
============

Epidemiological data suggest worse stroke outcomes with extremes of sustained hypo- or hypertension,^[@bibr1-2048004019856496]^ which has led to numerous clinical trials to determine if pharmacological lowering of blood pressure after stroke is beneficial. The results have been varied from positive through neutral to negative.^[@bibr2-2048004019856496][@bibr3-2048004019856496][@bibr4-2048004019856496]--[@bibr5-2048004019856496]^ Increased systolic blood pressure variability (BPV) in the days after ischemic and hemorrhagic stroke is associated with worse outcome.^[@bibr6-2048004019856496][@bibr7-2048004019856496]--[@bibr8-2048004019856496]^ A prior study by Sare et al. of blood pressure levels in the days after ischemic stroke used data from the Virtual International Stroke Trial Archive (VISTA)^[@bibr9-2048004019856496]^ and reported that increased BPV was associated with poor long-term functional outcome after ischemic stroke. However, Sare et al. did not examine the association with death. Although prior studies have reported a positive association between increased BPV and death, they have been limited by small or restricted cohorts.^[@bibr10-2048004019856496],[@bibr11-2048004019856496]^ Because the effect of BPV on stroke outcome remains controversial and may, in fact, be an epidemiologic epiphenomenon, we sought to examine the impact of increased BPV on death within 90 days of stroke onset with multiple statistical approaches in a large cohort of acute stroke patients in the VISTA database.

Methods {#sec2-2048004019856496}
=======

We conducted retrospective analyses of anonymized individual participant level data from the acute stroke section of the VISTA.^[@bibr12-2048004019856496]^ Because the data were de-identified, IRB approval was not required. VISTA collects anonymized data from completed clinical trials. As per VISTA regulations, the trial sources from which data are extracted cannot be revealed. However, data were extracted based on the availability of key analysis variables: age, sex, time since stroke onset, medical history, death, a 90-day modified Rankin Scale (mRS) and four or five blood pressure readings in the 24 h after study enrollment. The latter variable was considered during the exposure period. Our primary outcome was death within 90 days of study enrollment. We excluded patients who were lost to follow-up and patients who died during the exposure period. We calculated BPV during the exposure period for both systolic blood pressure (SBP) and diastolic blood pressure (DBP) using six statistical methodologies: standard deviation (SD), coefficient of variation (CV), average real variability (ARV), successive variation (SV), variation independent of mean (VIM), and residual SD (rSD). BPV formulas are: $\text{SD} = \sqrt{\left( \frac{1}{n\ –1} \right)\sum_{(i = 1)}^{(n)}{(BP_{i}\ –BP_{\mathit{mean}})}^{2}}$; $\text{rSD} = \sqrt{\frac{\sum^{}{(\mathit{BP} - \mathit{BPest})}^{2}}{n - 2}}$; $\text{CV} = \left( \frac{\text{SD}}{BP_{\mathit{mean}}} \right)\text{*}100$; $\text{ARV} = \left( \frac{1}{n–1} \right)\sum_{({i = 1})}^{({n - 1})}\left| {BP_{i + 1}\ –BP_{i}} \right|$; $\text{SV} = \sqrt{(1/(n\ –1))\sum_{(i = 1)}^{(n - 1)}{(BP_{i + 1}\ –BP_{i})}^{2})}$; and VIM = ($BP_{\mathit{mean}}\text{*~}$SD/${\overline{x}}^{p}$). We selected these methodologies based on prior literature that advocated multiple approaches to evaluating BPV, many of which take into account the distribution and linear trends of blood pressure in an effort to reduce the dependency of BPV on mean blood pressure level.^[@bibr6-2048004019856496],[@bibr13-2048004019856496]^ We report the mean values of BPV for patients who died versus those who survived to day 90 and tested for inter-group differences with Student's t-test.

To standardize our regression analyses, all measures of BPV were divided into terciles and we compared the highest tercile of BPV to the lowest. We fit the following logistic models to the primary outcome with the predictor variable of BPV: (1) unadjusted, (2) adjusted a priori for patient age, baseline NIH stroke scale (NIHSS), mean blood pressure and administration of tissue plasminogen activator (tPA), and (3) adjusted for all baseline demographic covariates with a p \< 0.1 in a stepwise backwards selection. We also fit a Cox proportional hazards model to the highest versus lowest tercile of SBP SD because of its relative ease for translational clinical use. We conducted a sensitivity analysis in which we excluded patients who received tPA. STATA 15.1 was used for all data analyses, with statistical significance defined as p \< 0.05.

Results {#sec3-2048004019856496}
=======

We included 1891 patients (see [Table 1](#table1-2048004019856496){ref-type="table"} for additional baseline demographics). The primary outcome of death within 90 days of stroke onset was met by 277 patients (14.7%). The mean (SD) number of days to death was 24.8 (22.9). The mean (SD) hours from stroke onset to study enrollment was 4.8 (2.4) and 534 (27.5%) patients received intravenous tPA. The median (interquartile range \[IQR\]) values of baseline NIHSS and 90-day mRS were 13 (9--18) and 3 (1--4). All indices of BPV were higher in patients who died ([Table 2](#table2-2048004019856496){ref-type="table"}), but the difference was more pronounced for systolic than diastolic BPV. Similar results were found in the logistic regression models fit to the outcome of death within 90 days of stroke onset, where only systolic BPV remained significant after adjustment for possible confounders ([Table 3](#table3-2048004019856496){ref-type="table"}). Mean blood pressure was not consistently predictive of death in any of our models. In the Cox model, which compared the risk of the highest tercile of SBP SD to the lowest, the hazard ratio for death was 1.59 (95% CI, 1.19--2.13), and remained significant after adjustment for the covariates in Models 2 and 3. The sensitivity analysis, where patients who received tPA were excluded, yielded near identical results.

###### 

Baseline demographics of the entire cohort compared between patients who died or survived in the 90 days after ischemic stroke onset.^[a](#table-fn1-2048004019856496){ref-type="table-fn"}^

![](10.1177_2048004019856496-table1)

  Variable                                                    Entire cohort (n=1891)   Alive at day 90 (n=1614)   Dead at day 90 (N=277)   p-Value
  ----------------------------------------------------------- ------------------------ -------------------------- ------------------------ ---------
  Age (mean  ±  SD)                                           69.5 ± 12.2              68.4 ± 12.3                75.7 ± 10.0              \<0.001
  Male sex (n, %)                                             1013, 53.6               865, 53.6                  148, 53.4                0.960
  Baseline NIHSS (median, IQR)                                13, 9--18                12, 8--17                  18, 14-21                \<0.001
  Hours from stroke onset to study enrollment (mean  ±  SD)   4.8 ± 2.4                4.7 ± 2.3                  5.4 ± 2.7                \<0.001
  History of hypertension (n, %)                              1392, 73.6               1177, 72.9                 215, 77.6                0.102
  History of diabetes (n, %)                                  425, 22.5                351, 21.8                  74, 26.7                 0.067
  History of prior stroke (n, %)                              364, 19.3                303, 18.8                  61, 22.0                 0.205
  History of myocardial infraction (n, %)                     239, 12.6                190, 11.8                  49, 17.7                 0.006
  History of atrial fibrillation (n, %)                       502, 26.6                394, 24.4                  108, 39.0                \<0.001
  Current smoker (n, %)                                       466, 24.6                450, 27.9                  16, 5.8                  \<0.001
  Left hemisphere stroke (n, %) (n=1888)                      917, 48.6                774, 48.0                  143, 51.6                0.271
  tPA administered (n, %)                                     506, 26.8                461, 28.6                  45, 16.3                 \<0.001

^a^Difference between continuous variables tested with Student's t-test, binary variables with the chi-squared test, and for ordinal variables with the Wilcoxon Rank Sum test.

###### 

Mean±SD values of BPV indices compared between patients who died or survived in the 90 days after ischemic stroke onset.

![](10.1177_2048004019856496-table2)

  BPV variable   Alive at day 90 (n=1614)   Dead at day 90 (N=277)   p-Value
  -------------- -------------------------- ------------------------ ---------
  SBP SD         13.4 ± 6.6                 15.9 ± 8.9               \<0.001
  SBP CV         9.1 ± 4.3                  10.6 ± 6.0               \<0.001
  SBP ARV        14.5 ± 7.9                 17.6 ± 9.9               \<0.001
  SBP SV         17.1 ± 9.0                 20.5 ± 11.3              \<0.001
  SBP VIM        13.9 ± 7.0                 16.0 ± 10.0              \<0.001
  SBP rSD        12.0 ± 7.0                 14.3 ± 8.7               \<0.001
  SBP mean       148.5 ± 19.5               151.8 ± 20.5             0.011
  DBP SD         9.2 ± 5.0                  10.0 ± 5.0               0.017
  DBP CV         11.9 ± 6.7                 12.9 ± 6.7               0.015
  DBP ARV        10.0 ± 5.9                 11.0 ± 6.1               0.008
  DBP SV         11.8 ± 6.7                 13.0 ± 6.8               0.010
  DBP VIM        9.5 ± 5.6                  10.4 ± 5.6               0.017
  DBP rSD        8.3 ± 5.1                  8.9 ± 5.1                0.053
  DBP mean       79.0 ± 12.2                78.6 ± 13.2              0.623

Note: DBP n = 1889 (1613 vs. 276). SD: standard deviation; CV: coefficient of variation; ARV: average real variability; SV: successive variation; VIM: variation independent of mean; rSD: residual SD; SBP: systolic blood pressure; DBP: diastolic blood pressure.

###### 

Logistic regression models fit to the outcome of death within 90 days, showing the comparison between the highest to lowest tercile for both SBP and DBP.
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          Model 1             Model 2   Model 3                                         
  ------- ------------------- --------- ------------------- ------- ------------------- -------
  SBP                                                                                   
   SD     1.68 (1.22, 2.30)   0.001     1.49 (1.05, 2.10)   0.024   1.55 (1.09, 2.19)   0.014
   CV     1.56 (1.14, 2.13)   0.005     1.72 (1.11, 2.20)   0.010   1.61 (1.15, 2.27)   0.006
   ARV    1.89 (1.38, 2.59)   \<0.001   1.58 (1.23, 2.22)   0.009   1.64 (1.16, 2.31)   0.005
   SV     1.84 (1.35, 2.51)   \<0.001   1.65 (1.17, 2.31)   0.004   1.74 (1.24, 2.44)   0.002
   VIM    1.41 (1.04, 1.91)   0.029     1.70 (1.19, 2.42)   0.004   1.61 (1.15, 2.26)   0.006
   rSD    1.63 (1.20, 2.21)   0.002     1.49 (1.07, 2.07)   0.020   1.61 (1.15, 2.26)   0.006
   Mean   1.55 (1.14, 2.11)   0.006     1.08 (0.77, 1.52)   0.662   1.14 (0.81, 1.61)   0.469
  DBP                                                                                   
   SD     1.41 (1.03, 1.93)   0.033     1.19 (0.85, 1.68)   0.310   1.32 (0.93, 1.88)   0.114
   CV     1.47 (1.07, 2.01)   0.017     1.26 (0.89, 1.79)   0.202   1.26 (0.89, 1.79)   0.194
   ARV    1.51 (1.11, 2.05)   0.008     1.30 (0.93, 1.81)   0.126   1.34 (0.96, 1.89)   0.088
   SV     1.54 (1.13, 2.10)   0.006     1.32 (0.94, 1.85)   0.108   1.41 (1.00, 2.00)   0.049
   VIM    1.52 (1.10, 2.09)   0.010     1.29 (0.90, 1.84)   0.168   1.25 (0.89, 1.80)   0.195
   rSD    1.43 (1.05, 1.94)   0.024     1.32 (0.94, 1.84)   0.105   1.43 (1.01, 2.00)   0.041
   Mean   0.92 (0.68, 1.25)   0.581     1.33 (0.95, 1.86)   0.097   1.34 (0.95, 1.88)   0.097

Note: Model 1: Unadjusted. Model 2: Adjusted for patient age, baseline NIH stroke scale score, administration of tPA, and mean blood pressure (apart from model that includes mean as the predictor). Model 3: Adjusted for patient age, sex, baseline NIH stroke scale score, current cigarette smoking, and stroke hemisphere (right vs. left). n = 1888 for SBP Model 3, n = 1889 for DBP Models 1 and 2, n = 1886 for DBP Model 3. SD: standard deviation; CV: coefficient of variation; ARV: average real variability; SV: successive variation; VIM: variation independent of mean; rSD: residual SD; SBP: systolic blood pressure; DBP: diastolic blood pressure.

Discussion {#sec4-2048004019856496}
==========

These results reinforce prior studies that found increased BPV is associated with worse neurologic outcome after stroke.^[@bibr6-2048004019856496]^ Specifically, we find that increased systolic BPV in the first day after ischemic stroke onset is associated with a higher risk of death within 90 days of stroke onset. This analysis expands on prior publications that found a similar association, but validates it in a larger cohort with rigorously adjudicated outcomes and the use of multiple statistical measures of BPV, which further strengthens the observed association.^[@bibr10-2048004019856496],[@bibr11-2048004019856496]^ The mechanism underlying the negative effects of BPV remains unknown, but considering the human body's preference for homeostasis in all central physiological processes, an increase in BPV remains a plausible mediator of worse outcome. Furthermore, without research demonstrating clinical benefit to reducing BPV, we cannot know if it is causal of adverse outcome or merely an epiphenomenon.

Our study has additional limitations, the most important being that this is a not a pre-specified analysis of these prospectively collected data. The relatively few numbers of BP readings and lack of control over the blood pressure measurement methodology limit the accuracy of the BPV calculations. Despite these limitations, these data should help guide research on BPV after stroke and advocate for the inclusion of death as a clinical outcome in future studies that therapeutically reduce BPV.
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